• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-05-30

  Oliveira et al. (2025) demonstrate that naturally occurring angiotensin peptides, including shorter fragments such as Angiotensin 1/2 (5-7), significantly enhance SARS-CoV-2 spike protein binding to the AXL receptor. These findings provide new insight into the intersection of renin-angiotensin system signaling and COVID-19 pathogenesis, highlighting emerging research pathways for both cardiovascular and viral infection studies.

• Uridine, Trisodium Salt: Enabling Precision RNA Engineering

  2026-05-29

  Explore how Uridine, Trisodium Salt accelerates translational breakthroughs in RNA biosynthesis and genome engineering. This thought-leadership article synthesizes mechanistic insight and strategic guidance for researchers, drawing on the latest advances in RNA-mediated transgene insertion and the competitive landscape of gene editing tools. Discover protocol parameters, application maturity, and a forward-looking vision for integrating nucleoside analogs into next-generation translational workflows.

• Coumestrol Induces Ferroptosis in RA Synoviocytes via PMAIP1

  2026-05-29

  The reference study reveals that Coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes by stabilizing mitochondrial PMAIP1 through TRIM3 suppression. This mechanistic insight highlights a promising therapeutic approach for targeting synovial proliferation and inflammation in RA.

• EPI-001: Advancing Androgen Receptor Inhibition for Prostate

  2026-05-28

  Discover how EPI-001, a leading androgen receptor N-terminal domain inhibitor, is transforming prostate and breast cancer research through its unique mechanism and translational applications. This article explores in-depth scientific insights, protocol guidance, and the latest evidence from AR-driven cancer models.

• T7 RNA Polymerase: Precision RNA Synthesis for Translational

  2026-05-28

  This thought-leadership article explores the mechanistic and strategic value of T7 RNA Polymerase (recombinant enzyme expressed in E. coli) for translational researchers, spotlighting its role in advanced gene editing and RNA-based therapeutics. Anchored by recent oncology findings and internal/external content, the article offers actionable insights beyond standard product narratives.

• EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Workf

  2026-05-27

  EPI-001 enables direct targeting of both full-length androgen receptor and its resistant splice variants, unlocking new frontiers in prostate and triple-negative breast cancer research. This guide translates recent breakthroughs into actionable protocols and troubleshooting strategies for robust, reproducible AR signaling pathway inhibition.

• Timescale-Dependent Phosphoproteomic Adaptation to Cabozanti

  2026-05-27

  This study applies quantitative phosphoproteomics to reveal how acute and chronic Cabozantinib (XL184) exposure differentially remodels phosphorylation networks in renal cell carcinoma (RCC). The findings demonstrate that chronic exposure leads to selective adaptation in adhesion- and motility-associated signaling, providing a framework for understanding resistance and informing future research on kinase inhibitor therapy.

• T7 RNA Polymerase: Strategic Leverage for Translational RNA

  2026-05-26

  This thought-leadership article explores the mechanistic foundation and translational strategy of using T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, as an enabling technology for in vitro RNA synthesis in the context of next-generation cancer immunotherapy and RNA therapeutics. By synthesizing recent breakthroughs in tumor microenvironment modulation and mRNA/siRNA delivery, the discussion connects foundational enzymology to the frontiers of clinical translation, with actionable guidance for researchers navigating the evolving RNA landscape.

• M344: Histone Deacetylase Inhibitor for Advanced Cancer Assa

  2026-05-26

  M344 is a potent, cell-permeable histone deacetylase inhibitor that empowers researchers to drive apoptosis and differentiation in challenging cancer models. This article translates cutting-edge NEUROBLASTOMA findings into actionable workflows, protocol enhancements, and troubleshooting insights—maximizing the impact of M344 supplied by APExBIO in translational oncology.

• Glycogen Colorimetric Assay Kit II: Advanced Glycogen Quanti

  2026-05-25

  The Glycogen Colorimetric Assay Kit II enables rapid, high-throughput detection of glycogen even in challenging biological samples. Its robust, interference-resistant workflow empowers metabolic, circadian, and glycogen storage disease research with unparalleled sensitivity and reproducibility.

• 2-NBDG: High-Resolution Glucose Uptake Assays for Metabolic

  2026-05-25

  2-NBDG, a fluorescent glucose analog, enables quantitative, high-resolution analysis of cellular glucose uptake using versatile platforms like flow cytometry and microscopy. This guide delivers practical protocols, troubleshooting insights, and advanced applications—including its role in dissecting glycolytic reprogramming in cancer—empowering researchers to unlock new frontiers in metabolic and disease modeling.

• T7 RNA Polymerase: Optimizing In Vitro Transcription Workflo

  2026-05-24

  Harness the specificity of recombinant T7 RNA Polymerase for high-yield, promoter-driven RNA synthesis in advanced molecular biology applications. This article decodes practical setup, cutting-edge workflow enhancements, and expert troubleshooting, offering a bridge between foundational research and translational breakthroughs in RNA-based technologies.

• Protease Inhibitor Cocktail EDTA-Free: Precision Beyond Extr

  2026-05-23

  Discover how the Protease Inhibitor Cocktail (EDTA-Free) empowers complex protein studies by safeguarding proteome integrity without EDTA interference. This in-depth analysis explores advanced applications and unique assay design insights, setting a new benchmark for protein extraction and downstream compatibility.

• Syringin: Mechanistic Insights and Translational Value in RC

  2026-05-22

  Explore the unique mechanistic depth of Syringin, a bioactive natural product, and its emerging translational value in renal cell carcinoma (RCC) research. This article connects molecular action, protocol design, and assay selection to practical advances in natural product research.

• N1-Methylpseudouridine: Optimizing mRNA Translation in Diagn

  2026-05-22

  N1-Methylpseudouridine enables robust mRNA translation with reduced immunogenicity, empowering sensitive functional assays in disease modeling and diagnostics. This guide details best-practice workflows, troubleshooting strategies, and lessons from cutting-edge CRISPRa-based splicing variant analysis.

15149 records 1/1010 page Next 12345 下5页 Last page